Lei Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Yu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Wei Chen
Urinary Surgery, Medical Innovation Technology Transformation Center, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Institute for Advanced Study, Synthetic Biology Research Center, International Cancer Center of Shenzhen University, Shenzhen 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen 518035, Guangdong Province, China
3 shared publications - Weiren Huang
The First Affiliated Hospital, Shenzhen University; Shenzhen Second People’s Hospital; Medical Innovation Technology Transformation Center of Shenzhen Second People’s Hospital, Institute for Advanced Study, Synthetic Biology Research Center, International Cancer Center of Shenzhen University, Shenzhen, 518039, China
2 shared publications - Zhichao Li
Medical Innovation Technology Transformation Center Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University Institute for Advanced Study Synthetic Biology Research Center Shenzhen University Shenzhen People's Republic of China
2 shared publications Dong Chen
Shenzhen Second People’s Hospital The First Affiliated Hospital of Shenzhen University Shenzhen China
1 shared publication- Dong Chen
Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, Guangdong, China
1 shared publication Dong Li
National Centre for AIDS/STD Control and Prevention, China CDC, Beijing, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 8 July 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (7) , e970
Patient‐derived renal cell carcinoma organoids for personalized cancer therapy
Background: Kidney cancer is one of the most common solid tumors. The advancement of human kidney cancer research and treatment has been hindered by a lack of research models that faithfully recapitulate the diversity of the disease.Methods: We established an effective three‐dimensional culture system for generating kidney cancer organoids from clinical renal cell carcinoma samples. Renal cell carcinoma (RCC) organoids were characterized by H&E staining, immunofluorescence, whole‐exome sequencing, RNA sequencing and single‐cell RNA sequencing. The use of RCC organoids in personalized cancer therapy was assessed by testing their responses to treatment drugs and chimeric antigen receptor T cells.Results: Using this organoid culture system, 33 kidney cancer organoid lines from common kidney cancer subtypes, including clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell carcinoma (chRCC), were generated. RCC organoids preserved the histological architectures, mutational landscapes, and transcriptional profile of the parental tumor tissues. Single‐cell RNA‐sequencing revealed inter‐ and intra‐tumoral heterogeneity in RCC organoids. RCC organoids allowed for in vitro drug screening and provided a tool for assessing the efficacy of chimeric antigen receptor T cells.Conclusions: Patient‐derived RCC organoids are valuable pre‐clinical models for academic research and personalized medicine.
- 8 July 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (7) , e970
Top Cited PapersOpen AccessPatient‐derived renal cell carcinoma organoids for personalized cancer therapy
Background: Kidney cancer is one of the most common solid tumors. The advancement of human kidney cancer research and treatment has been hindered by a lack of research models that faithfully recapitulate the diversity of the disease.Methods: We established an effective three‐dimensional culture system for generating kidney cancer organoids from clinical renal cell carcinoma samples. Renal cell carcinoma (RCC) organoids were characterized by H&E staining, immunofluorescence, whole‐exome sequencing, RNA sequencing and single‐cell RNA sequencing. The use of RCC organoids in personalized cancer therapy was assessed by testing their responses to treatment drugs and chimeric antigen receptor T cells.Results: Using this organoid culture system, 33 kidney cancer organoid lines from common kidney cancer subtypes, including clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell carcinoma (chRCC), were generated. RCC organoids preserved the histological architectures, mutational landscapes, and transcriptional profile of the parental tumor tissues. Single‐cell RNA‐sequencing revealed inter‐ and intra‐tumoral heterogeneity in RCC organoids. RCC organoids allowed for in vitro drug screening and provided a tool for assessing the efficacy of chimeric antigen receptor T cells.Conclusions: Patient‐derived RCC organoids are valuable pre‐clinical models for academic research and personalized medicine.
- Open Access
- 1 March 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (1) , 100239
Protocol for generation of lung adenocarcinoma organoids from clinical samples
- 1 March 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (1) , 100239
Open AccessProtocol for generation of lung adenocarcinoma organoids from clinical samples
- Open Access
- 31 January 2021
- Published by Wiley in Clinical & Translational Immunology
- Vol. 10 (2) , e1248
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro
Objectives: Recent advances in patient‐derived cancer organoids have opened a new avenue for personalised medicine. We aimed to establish an in vitro technological platform to evaluate chimeric antigen receptor (CAR)‐T cell‐mediated cytotoxicity against bladder cancer.Methods: Patient‐derived bladder cancer organoids (BCOs) were derived using classic medium containing R‐spondin 1 and noggin. The features of BCOs were characterised via H&E, whole‐exome sequencing and immunofluorescence of specific markers. Surface antigen expression profiles of the recently identified CAR‐recognisable targets were determined with a panel of antibodies via immunohistochemistry. A co‐cultivation system consisting of BCOs and engineered T cells targeting a specific antigen was utilised to test its efficacy to model immunotherapy by cytotoxic assays and ELISA.Results: Bladder cancer organoid lines of basal and luminal subtypes were established. The histopathological morphology, genomic alteration, and specific marker expression profiles showed that the BCO lines retained the characteristics of the original tumors. Among all tested CAR‐recognisable antigens in other solid tumors, MUC1 was simultaneously expressed in organoids and parental tumor tissues. Given the surface antigen profiles, second‐generation CAR‐T cells targeting MUC1 were prepared for modelling in vitro immunotherapy responses in BCOs. Specific immune cytotoxicity occurred only in the MUC1+ organoids but not in the MUC1‐ organoids or control CAR‐T cells.Conclusion: Patient‐derived BCOs recapitulate the heterogeneity and key features of parental cancer tissues, and these BCOs could be useful for preclinical testing of CAR‐T cells in vitro.
- 31 January 2021
- Published by Wiley in Clinical & Translational Immunology
- Vol. 10 (2) , e1248
Open AccessPatient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro
Objectives: Recent advances in patient‐derived cancer organoids have opened a new avenue for personalised medicine. We aimed to establish an in vitro technological platform to evaluate chimeric antigen receptor (CAR)‐T cell‐mediated cytotoxicity against bladder cancer.Methods: Patient‐derived bladder cancer organoids (BCOs) were derived using classic medium containing R‐spondin 1 and noggin. The features of BCOs were characterised via H&E, whole‐exome sequencing and immunofluorescence of specific markers. Surface antigen expression profiles of the recently identified CAR‐recognisable targets were determined with a panel of antibodies via immunohistochemistry. A co‐cultivation system consisting of BCOs and engineered T cells targeting a specific antigen was utilised to test its efficacy to model immunotherapy by cytotoxic assays and ELISA.Results: Bladder cancer organoid lines of basal and luminal subtypes were established. The histopathological morphology, genomic alteration, and specific marker expression profiles showed that the BCO lines retained the characteristics of the original tumors. Among all tested CAR‐recognisable antigens in other solid tumors, MUC1 was simultaneously expressed in organoids and parental tumor tissues. Given the surface antigen profiles, second‐generation CAR‐T cells targeting MUC1 were prepared for modelling in vitro immunotherapy responses in BCOs. Specific immune cytotoxicity occurred only in the MUC1+ organoids but not in the MUC1‐ organoids or control CAR‐T cells.Conclusion: Patient‐derived BCOs recapitulate the heterogeneity and key features of parental cancer tissues, and these BCOs could be useful for preclinical testing of CAR‐T cells in vitro.
- Open Access
- 21 February 2018
- Published by Wiley in Immunology
- Vol. 154 (4) , 651-662
Molecular characteristics of rhesus macaque interleukin‐22: cloning, in vitro expression and biological activities
Summary: Interleukin‐22 (IL‐22) is a potential therapeutic agent for diseases driven by epithelial injury. To characterize the IL‐22 expressed by rhesus macaques, animals that are irreplaceable for human disease research, rhesus macaque IL‐22 (rhIL‐22) was cloned and expressed, and its biological activity and in vivo distribution were examined. It was found that the rhIL‐22 gene consists of five introns and six exons, including a short non‐coding exon starting 22 bp downstream of a putative TATA box. The amino acid sequence of rhIL‐22 showed 95·5% identity to that of humans, and it shared two conserved disulphide bonds, three N‐glycosylation sites and all the critical residues for binding to IL‐22R1. High levels of IL‐22 mRNA were observed in the liver, pancreas, lymphoid tissues and especially in the outer‐body barriers such as the intestinal tract of rhesus macaques. Functionally, purified rhIL‐22 has a similar but a little earlier effect on signal transducer and activator of transcription 3 phosphorylation at Tyr705 compared with that of commercial human IL‐22. The expression of the antibacterial proteins β‐defensin‐2, S100A8, S100A9, RegIIIα and Muc1 by HT‐29 cells was largely upregulated after stimulation with rhIL‐22. Recombinant rhIL‐22 could also significantly promote the proliferation of human intestinal epithelial cells without affecting cell apoptosis. These data indicate that rhesus macaque IL‐22 is highly similar to that of humans in both structure and function, and tests of therapeutic effects of human IL‐22 on human diseases in rhesus macaques are warranted.
- 21 February 2018
- Published by Wiley in Immunology
- Vol. 154 (4) , 651-662
Open AccessMolecular characteristics of rhesus macaque interleukin‐22: cloning, in vitro expression and biological activities
Summary: Interleukin‐22 (IL‐22) is a potential therapeutic agent for diseases driven by epithelial injury. To characterize the IL‐22 expressed by rhesus macaques, animals that are irreplaceable for human disease research, rhesus macaque IL‐22 (rhIL‐22) was cloned and expressed, and its biological activity and in vivo distribution were examined. It was found that the rhIL‐22 gene consists of five introns and six exons, including a short non‐coding exon starting 22 bp downstream of a putative TATA box. The amino acid sequence of rhIL‐22 showed 95·5% identity to that of humans, and it shared two conserved disulphide bonds, three N‐glycosylation sites and all the critical residues for binding to IL‐22R1. High levels of IL‐22 mRNA were observed in the liver, pancreas, lymphoid tissues and especially in the outer‐body barriers such as the intestinal tract of rhesus macaques. Functionally, purified rhIL‐22 has a similar but a little earlier effect on signal transducer and activator of transcription 3 phosphorylation at Tyr705 compared with that of commercial human IL‐22. The expression of the antibacterial proteins β‐defensin‐2, S100A8, S100A9, RegIIIα and Muc1 by HT‐29 cells was largely upregulated after stimulation with rhIL‐22. Recombinant rhIL‐22 could also significantly promote the proliferation of human intestinal epithelial cells without affecting cell apoptosis. These data indicate that rhesus macaque IL‐22 is highly similar to that of humans in both structure and function, and tests of therapeutic effects of human IL‐22 on human diseases in rhesus macaques are warranted.